DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1575)

TreatmentTrends: Multiple Sclerosis (US) Q3 2013

BioTrends Research Group is pleased to announce the continuation of TreatmentTrends®: Multiple Sclerosis (US) report series in 2013. Each biannual report examines the current trends in the management of multiple sclerosis (MS) from the perspective of neurologists.
TreatmentTrends® are syndicated report series that provide longitudinal information on market dynamics. They provide insight into practice patterns, attitudes and perceptions, and current and projected use of various products. TreatmentTrends® evaluate perceived product advantages and disadvantages, as well as sales and messaging efforts of key market players.

Questions Answered in This Report:

  • Understand the relative MS patient load by disease classification (CIS, RRMS, PRMS, SPMS, PPMS) and how DMAs are used in each group

  • Understand product attributes that are most important to neurologists when selecting DMAs and compare the different brands on how they are perceived to perform against each attribute

  • Understand how the use of each DMA brand is expected to change in the next six months and what factors are driving those trends

  • Evaluate sales strategies and messaging efforts of DMA therapies

  • Assess awareness of and interest in DMA therapies that are in late stage development


Sample Frame & Methodology:

~100 neurologists complete a 45 minute online quantitative survey with several open ended questions for qualitative feedback

To qualify, respondents meet the following criteria:

- Minimum of 20 patients with relapsing remitting multiple sclerosis under management

- Have been in practice a minimum of 2 years and a maximum of 35 years

- More than 75% of professional time spent in clinical practice


- Final report in powerpoint format

- Tracking between waves will be provided for clients purchasing the report series

- Complete set of frequency tables, summary statistics, and cross tabulations can be provided upon request

- Proprietary question slide deck and frequency tables

- Clients purchasing prior to fielding will have the opportunity to include up to three proprietary questions in each wave

Product Coverage:

- Approved: Aubagio, Avonex, Betaseron, Copaxone, Extavia, Gilenya, Rebif, Tysabri, Ampyra

- In development: Copaxone 40mg 3x weekly, daclizumab, laquinimod, Lemtrada, ocrelizumab, PEG-Avonex, Tecfidera

Related 2013 Reports:

- TreatmentTrends®: Multiple Sclerosis (EU)

- LaunchTrends®: Aubagio (US)

- LaunchTrends®: Lemtrada (US)

- LaunchTrends®: Tecfidera (US)

- DecisionBase®: Multiple Sclerosis-Chronic Progressive

- DecisionBase®: Multiple Sclerosis-Relapsing Remitting

- PatientBase®: Multiple Sclerosis in Mexico

- PatientBase®: Multiple Sclerosis in Turkey

- PatientBase®: Multiple Sclerosis in South Korea

- Treatment Algorithms®: Multiple Sclerosis

- Pharmacor®: Multiple Sclerosis

- Physician and Payer Forum®: Multiple Sclerosis